Does Q33.9 require prior authorization?

No, Q33.9 does not require prior authorization (high confidence). Covered without prior authorization.

`Q33.9`, Congenital malformation of lung, unspecified

ICD-10-CM

No Prior Auth Required

Covered without prior authorization (high confidence)

This billing/coding guideline complements LCD L33459 (Computerized Axial Tomography (CT), Thorax); follow the LCD for clinical coverage and any required documentation or prior authorization rules.
Documentation of conventional/prior therapies attempted (high concentrations of oxygen, ventilatory support, surfactant, high-frequency ventilation, alkalosis induction, neuromuscular blockade, etc.) and rationale for iNO as rescue/adjunct therapy.
Device and dosing records showing administration via FDA-approved device (e.g., INOmax) and recorded dose and duration.
Monitoring records: methemoglobin levels and nitrogen dioxide (NO2) monitoring (trials used continuous spectrophotometric monitoring of methemoglobin), and renal function monitoring for adult patients given risk of renal impairment.

Aetna considers inhaled nitric oxide (INO) therapy medically necessary as a component of the treatment of hypoxic respiratory failure in neonates 34 weeks gestation or greater when both of the following criteria are met: Neonates do not have congenital diaphragmatic hernia; and When conventional therapies such as administration of high concentrations of oxygen, hyperventilation, high-frequency ventilation, the induction of alkalosis, neuromuscular blockade, and sedation have failed or are expect [...]
Aetna considers INO therapy medically necessary for post-operative management of pulmonary hypertensive crisis in infants and children with congenital heart disease.
Aetna considers the diagnostic use of INO medically necessary as a method of assessing pulmonary vaso-reactivity in persons with pulmonary hypertension.
Use as adjunct or rescue therapy in perioperative pulmonary hypertensive crisis during congenital heart surgery
Q33.1 Accessory lobe of lung
Q33.2 Sequestration of lung

AMBETTER-CP.MP.242, Pulmonary Function Testing

AETNA-CPB-0318, Palivizumab (Synagis)

AETNA-CPB-0518, Nitric Oxide, Inhalational (INO)

A56580, Billing and Coding: Computerized Axial Tomography (CT), Thorax

Ask Backwork about documentation requirements, denial risks, or coverage in your state.